HYDERABAD: Dr Reddy's Laboratories
has posted 32.4% jump in quarterly net profit since its sales in its key North America market rose.
The drug manufacturer stated that the consolidated net profit climbed to Rs 4.07 billion in the second quarter ended September as compared to Rs 3.08 billion a year back. Moreover, income from sales and services climbed 27% to Rs 28.81 billion during the September quarter.
Dr Reddy’s Laboratories Limited operates as an integrated pharmaceutical company. It operates in three segments: Pharmaceutical services and Active Ingredients (PSAI), Global Generics, and Proprietary Products. The PSAI segment develops active pharmaceutical ingredients (APIs) and intermediaries, which are used as principal ingredients for finished pharmaceutical products.